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Abstract 
Pertussis is an acute infectious disease caused by the organ-
ism Bordetella pertussis and characterized by a "whooping 
cough." Incidence of the disease had declined since the devel-
opment of a vaccine, but is now increasing in reported cases. 
This increase has been attributed to both an increased 
awareness but also surmised to be related to a decrease in 
vaccinations. The pertussis vaccine is given in conjunction 
with tetanus and diphtheria vaccines to children before the 
age of 6 in five separate injections over the course of four to 
six years. A booster is now recommended for the older child 
and adults due to the declining protection of the vaccine over 
time. Pertussis is highly contagious and early treatment with 
a macrolide antibiotic is recommended to limit the severity 
and prevent transmission. It can be deadly in infants, which 
is why prevention via immunizations is so important. The 
pharmacist can assist with advising individuals of the impor-
tance of vaccination. 
Introduction 
Pertussis, also known as whooping cough, is an acute infec-
tious disease caused by the organism Bordetella pertussis 
that has a history of being a common preventable yet fatal 
childhood disease. Since the development of the pertussis 
vaccine in the 1940s, the incidence rate has decreased by at 
least 75 percent among children. But recently, the number of 
reported cases of pertussis has increased. The Centers for 
Disease Control and Prevention (CDC) believes that this in-
crease could be due to heightened awareness and improve-
ment in clinicians' ability to diagnose pertussis, but they also 
believe that a large portion of the disease goes unreported or 
unrecognized.1 According to the Council on Foreign Rela-
tions, since 2008 there have been 65,457 reported pertussis 
outbreaks around the world with an astonishing 56.4 percent 
of those cases happening in the United States.2 Due to rapid 
spread of disease, these outbreaks usually occur in clusters. 
Over the years, these clusters of outbreaks experience peaks 
of incidence every three to five years and continue to follow 
this same pattern.3 With the use of patient education on signs 
and treatment of pertussis as well as prevention and vaccina-
tion, this recent spike in incidence rate can be controlled. 
Disease State 
Bordetella pertussis is a gram-negative bacteria that pro-
duces many biologically active products, most notably the 
pertussis toxin (PT). Pertussis toxin modifies inhibitory G 
proteins rendering them unable to inhibit adenylyl cyclase, 
an enzyme that plays an essential role in transmitting signals 
to secondary messengers. Thus, PT forces other activated G 
proteins into continuous signaling, leading to various un-
wanted consequences such as immune suppression, which 
would promote bacterial colonization and potentially in-
crease transmission of the disease.4 Physiologically, Borde-
tella pertussis attaches to the cilia of respiratory epithelial 
cells and paralyzes them. This causes pulmonary secretions 
to be inadequately cleared and leads to inflammation in the 
respiratory tract.1 
This very contagious disease is spread from person to per-
son, most commonly by inhalation of droplets from a cough 
or a sneeze.5 Symptoms usually start to occur within seven to 
10 days of initial transmission. These symptoms start off as 
cold-like with a runny nose and mild cough along with a low-
grade fever. This can develop into a severe cough or apnea, a 
pause in breathing pattern that is very common in infants. 
This severe cough can become so violent and rapid that all 
the air from the lungs is expelled and the patient is forced to 
inhale, which results in the characteristic "whooping" sound. 
These severe coughs can cause young children to vomit and 
become extremely lethargic.6 Complications that occur in 
infants and children include pneumonia, convulsions, severe 
apnea, encephalopathy or even death. In teens and adults, 
complications can include weight loss, loss of bladder con-
trol, passing out or even rib fractures from severe coughing.7 
Infants develop the most severe complications of pertussis 
because their immune systems are not fully developed at 
birth and cannot offer full protection against the disease. Al-
though receiving vaccines helps infants fight certain diseases, 
they are still vulnerable to disease until their immune system 
is fully developed. If left untreated, these complications can 
lead to hospitalization of young children and infants in which 
one to two out of 100 infants will die due to pertussis.7 Diag-
nosis of pertussis involves evaluation of symptoms, a physi-
cal exam and a laboratory test of respiratory secretions. 
These secretions are taken from the back of the throat 
through the nose and are further evaluated for the presence 
of Bordetella pertussis.a 
Prevention 
The recommended form of prevention for pertussis is 
through immunizations.9 Two vaccines providing pertussis 
protection are available; Pediatric Diphtheria, Tetanus, and 
acellular Pertussis vaccine (DTaP) and Adult Tetanus, diph-
theria, and acellular pertussis vaccine (Tdap). The use of the 
upper-case letters in the abbreviations designate the doses of 
tetanus (T) and diphtheria (D) toxoids, and pertussis (P) vac-
cine are full-strength. Reduced doses of diphtheria and per-
tussis are represented by the lower-case "d" and "p" in the 
adult vaccination. The lowercase "a" in both vaccines repre-
sents "acellular" which means only part of the pertussis or-
ganism is present.1° The DTaP is administered to children 6 
years and younger in five separate doses usually occurring at 
ages 2 months, 4 months, 6 months, 15 to 18 months and 4 to 
6 years. The Tdap is recommended for children ages 7 to 18 
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if they have not been fully vaccinated which means they have 
not received all five doses of DTaP. If they have not received 
either the DTaP or Tdap vaccines before, adults ages 19 and 
older should receive a dose of Tdap as soon as possible to 
protect themselves.11 
Along with first time protection, Tdap is also employed as a 
booster available for older children and adults ages 11 to 64 
years, and is especially recommended for patients when 
coming into contact with infants. Adults may receive Tdap 
instead of their next scheduled tetanus booster shot, which 
are usually administered every 10 years. This dose of Tdap 
can be given before the next 10-year mark.11 Recent studies 
have shown that the immunity generated by these vaccines, 
especially DTaP, decreases over time. This waning immunity 
has led to numerous outbreaks affecting previously immu-
nized individuals. One report studied a population of chil-
dren between ages 4 and 12 and placed them into groups 
based on if they possessed pertussis. It was found that every 
year after receiving their fifth dose of the DTaP vaccine, the 
children had a 42 percent increased probability in obtaining 
pertussis.12 This means the DTaP vaccine would only be 
71 percent effective five years after administration when it 
was 95 percent effective initially.13 The results of this study 
highlight the need for children to receive boosters of the 
Tdap vaccine in order to stop this waning immunity. 
Special considerations about receiving the Tdap vaccine are 
made for pregnant women, health care professionals and the 
elderly. During each pregnancy, a woman should receive a 
dose ofTdap at 27 to 36 weeks to transfer pertussis antibod-
ies to her baby and to protect herself. These antibodies pro-
vide the newborn with protection until they begin receiving 
DTaP vaccines after birth. If the mother has not received 
Tdap, it is recommended she receive the vaccine in the post-
partum period, up to six weeks after birth. Adults 65 years or 
older should receive a single dose of the Tdap vaccine. 11 
Health care personnel, such as pharmacists, who work in 
close contact with patients and have not previously been ad-
ministered the Tdap vaccine should receive it to prevent 
spreading pertussis to their patients. 
Of course, if a child or adult is moderately or severely ill or 
allergic to any ingredients, they should not receive either 
vaccine.14 In general, the ingredients of purified DTaP /Tdap 
vaccines administered in the United States contain reduced 
pertussis toxin, trace amounts of mercury and an aluminum 
adjuvant.15 The mechanism of action of these vaccines to pre-
vent pertussis is not fully known, but an immune response is 
stimulated and protective antibodies are formed. Along with 
vaccines, prevention using post-exposure prophylaxis in at-
risk individuals who have come in contact with a contami-
nated person can be avoided with the use of prophylactic 
antibiotics including azithromycin, clarithromycin and eryth-
romycin.16 These antibiotics are known as macrolides which 
have bacteriostatic activities.17 
As the most accessible health care professionals, pharmacists 
are able to play a large role in the prevention of pertussis. In 
most states, pharmacists are able to administer the Tdap vac-
cine to patients ages 10 and older who have a prescription.ls 
This places pharmacists at the center of pertussis prevention. 
Since retail pharmacists are in constant contact with pa-
tients, it proposes the chance to ask high-risk populations, 
pregnant women and elderly, if they have received their 
Tdap vaccines. Plus, by examining prescriptions and commu-
nicating with patients, pharmacists can recognize if someone 
is being treated for pertussis. This provides the pharmacist 
with an opportunity to counsel the patient about the danger 
of pertussis to infants and ways to minimize the spread of 
pertussis like good hand washing. Overall, pharmacists pos-
sess the ability to educate their communities about pertussis 
prevention while also administering the Tdap vaccine. 
Acute Treatment 
Even though multiple prevention techniques against pertus-
sis exist, in 2012, the United States experienced 48,277 cases 
of pertussis reported to the CDC. 19 Although prophylactic 
antibiotics are used to prevent the development of pertussis 
in at-risk individuals, these antibiotics are mainly used to 
treat those already afflicted by the illness. Antibiotics includ-
ing azithromycin, clarithromycin and erythromycin are com-
monly employed treatment medications. Because erythro-
mycin and clarithromycin have a higher propensity to cause 
gastrointestinal irritation, azithromycin is the preferred anti-
biotic to be used in pertussis treatment. When used in pa-
tients 6 months and older, a 10 mg/kg single dose is given on 
day 1 and then a 5 mg/kg single dose is administered days 2 
through 5. The second-line option is clarithromycin given as 
two divided doses of 15 mg/kg/day to patients over 1 month 
old for seven days. A doctor can also prescribe erythromycin 
for pertussis treatment which is typically given as four 
divided daily doses of 40 to 50 mg/kg/day administered for 
14 days to patients over 1 month old. At least five days of 
treatment are required before the patient should leave isola-
tion, and it is important for the patient to complete the drug 
schedule fully.zo Since this disease is highly contagious, those 
with pertussis should stay isolated and avoid contact with 
other people, especially the unimmunized and infants. Early 
treatment is necessary to stop pertussis from spreading, and 
if the medications are administered before coughing fits be-
gin, the severity can be decreased. These medications only 
reduce the person's infectivity and do not alter the disease's 
clinical course. Once the individual has been infected with 
pertussis for three weeks, the medications are not useful be-
cause the bacteria is now absent from the body.s 
Along with antibiotics, simple adjustments can aid the treat-
ment of pertussis and stop its spread. Those individuals suf-
fering from pertussis should drink plenty of fluids to avoid 
dehydration. Plus, minimizing irritants such as smoke and 
dust along with using a cool mist vaporizer helps alleviate an 
ill person's cough. A key way to stop the spread of pertussis 
is as simple as good hand washing. Overall, the treatment 
options for pertussis stop the spread and decrease the sever-
ity of pertussis. More serious cases of pertussis may require 
hospitalization, especially in infants.3 Since pharmacists are 
very accessible, counseling patients on these treatment 
points is convenient and beneficial to the community. 
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Special Populations 
There are many special populations who are strongly ad-
vised to get the pertussis vaccine. The first population is 
infants and children, in which the highest incidence rate of 
pertussis occurs. Along with the vaccine, parents should be 
advised to keep their children away from anyone with cold 
symptoms or anyone coughing. The second population is 
caregivers of infants, who should get the vaccine and practice 
good hygiene in order to prevent them from spreading per-
tussis to children. Caregivers can collectively include parents, 
babysitters and other adults who have close contact fre-
quently with young children. Another population that is rec-
ommended to get the vaccine is pregnant women or anyone 
around a pregnant woman or newborn. This is also a preven-
tion measure taken to protect the child from contracting per-
tussis soon after birth. A more general population is anyone 
above preteen age who has not had a booster vaccine. This is 
solely for prevention of any future pertussis infection and to 
ensure that the individual has the maximum protection avail-
able. This is especially stressed in the elderly population in 
which immune systems are not as strong. Finally, interna-
tional travelers should be especially cautious about hygiene 
and being up to date on the vaccine. Traveling to other coun-
tries that have outbreaks of pertussis can put a traveler at 
great risk to contract that disease, and it also heightens the 
risk that the traveler will bring the disease back to their 
country and cause an outbreak there.9 
Disease Epidemiology 
Even with vaccinations available to protect a majority of the 
population, pertussis is still considered as endemic within 
the United States.3 Since 2003, pertussis has been on the rise 
in the Midwest and California.21 Reported cases of pertussis 
across the country jumped to 48,277 cases in 2012, from 
18,719 cases in 2011. A general increase in reporting is to 
blame for a portion of the jump, but the doubling in reported 
cases is troubling given that pertussis is easily preventable. 
While most cases of pertussis can be treated with little to no 
lasting sequelae, cases in infants can be especially severe, 
with high mortality rates.22 The importance of herd immu-
nity has emerged over the years while the number of re-
ported pertussis cases continues to climb. 
In 2010, the United States saw its largest pertussis outbreak 
since 194 7, in a Californian community. With 9,120 reported 
cases and 10 deaths, this outbreak was one of the first to be 
studied in relation to vaccination rates. Atwell et al. studied 
the rate of pertussis spread among clusters of nonmedical 
exemptions (NME) in kindergartners. Californian parents 
obtained NMEs if vaccines were seen to be against their reli-
gious or philosophical beliefs. Using the Californian Depart-
ment of Health's reported pertussis data and Kulldorff spatial 
scans, Atwell et al. found statistically significant higher rates 
of pertussis among communities with higher rates of NMEs. 
This study provides health care professionals with a strong 
correlation between vaccinations and pertussis prevention.21 
In describing the importance of vaccinations to the preven-
tion of pertussis to patients, a term commonly used is "herd 
immunity." Herd or community immunity is defined by the 
National Institute of Allergy and Infectious Disease as immu-
nizing a critical portion of the population against a disease, 
thereby preventing an outbreak and protecting a smaller 
portion of the population which may not be able to receive 
vaccinations due to health or other rationale.23 Childhood 
diseases such as polio and measles are essentially unheard of 
in first world countries due to the high vaccination rates 
among the children able to receive vaccinations. This high 
vaccination rate and immunity protects patients who may 
not be able to receive vaccinations due to disease states that 
may leave them immunocompromised or resistant to vacci-
nation. As the number of people opting out of vaccinations 
grows, the herd immunity of communities within the United 
States weakens. This is especially troubling due to the dis-
ease's severe threat to infants. By informing patients of this 
concept while promoting vaccinations, high-risk populations 
can be easily protected until they are able to receive the vac-
cination themselves. 
Conclusion 
Pharmacists are one of the most readily available health care 
professionals and can therefore play an important role in 
counseling patients on the pertussis vaccination. When coun-
seling patients about important vaccinations, pharmacists 
may run into patients hesitant to vaccinate due to many dif-
ferent reasons. The most common reasons include a belief 
that the vaccine-prevented disease no longer poses any risk, 
a doubt in the safety of the vaccine or a belief that the vaccine 
may overload a child's immune system or be linked to autism 
(which has been proven to be incorrect in multiple peer-
reviewed studies). Conservative forms of Islam, Judaism and 
Christianity have reasons against vaccinations, often because 
of the production or contents of the vaccine. When counsel-
ing parents who are vaccine-hesitant, Dr. John Harrington 
outlines eight points that health care professionals should 
keep in mind. First, health care professionals should begin 
having vaccination conversations early (such as an infant's 
first pediatrician visit), and pharmacists can distribute vac-
cine information sheets often to promote questions and con-
versations. While counseling, it is important to take the time 
to listen to all questions without patronizing the patient. 
Health care professionals should never offend the patient or 
become offended by earnest questions. Acknowledging 
possible peer-reviewed risks, using clear, patient-friendly 
language, and respecting a patient's authority in decision-
making allows for open conversations with patients about 
vaccinations. Pharmacists can also explain the reduction of 
pain for children receiving vaccinations through the use of 
sucrose or swaddling.24 Community pharmacists can play a 
role in many of these steps by being available for patients 
with questions. Taking extra time to explain vaccinations or 
distribute educational material to the patient who has 
become a new parent, will add on to the information many 
parents will be receiving from their child's pediatrician. By 
educating vaccine-hesitant patient populations, pharmacists 
can help increase pertussis vaccination rates and help 
reverse the outbreak trend. 
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